Press coverage about Vericel Corporation (NASDAQ:VCEL) has trended somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Vericel Corporation earned a daily sentiment score of 0.14 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 46.6134763675202 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the news stories that may have impacted Accern Sentiment Analysis’s scoring:
- Analyzing Anika Therapeutics (ANIK) & Vericel Corporation (VCEL) (americanbankingnews.com)
- Vericel Corporation (VCEL) Scheduled to Post Quarterly Earnings on Tuesday (americanbankingnews.com)
- ETFs with exposure to Vericel Corp. : October 26, 2017 (finance.yahoo.com)
- Vericel to Host Third-Quarter 2017 Earnings Webcast and … – GlobeNewswire (press release) (globenewswire.com)
- Vericel to Host Third-Quarter 2017 Earnings Webcast and Conference Call on November 7, 2017 (finance.yahoo.com)
Shares of Vericel Corporation (NASDAQ:VCEL) traded up 3.41% during trading on Tuesday, hitting $4.55. 305,683 shares of the stock traded hands. The company has a 50 day moving average price of $4.84 and a 200 day moving average price of $3.56. The firm’s market cap is $149.35 million. Vericel Corporation has a 12 month low of $2.00 and a 12 month high of $6.30.
Vericel Corporation (NASDAQ:VCEL) last announced its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.16. The company had revenue of $16.95 million for the quarter. Analysts anticipate that Vericel Corporation will post ($0.62) earnings per share for the current fiscal year.
Several equities analysts have recently weighed in on VCEL shares. Piper Jaffray Companies reiterated a “buy” rating and set a $7.00 price objective on shares of Vericel Corporation in a report on Thursday, August 10th. BTIG Research reiterated a “buy” rating and set a $6.00 price objective on shares of Vericel Corporation in a report on Thursday, September 7th.
TRADEMARK VIOLATION WARNING: “Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Vericel Corporation (VCEL) Stock Price” was originally published by Community Financial News and is the property of of Community Financial News. If you are reading this news story on another site, it was stolen and republished in violation of US and international copyright & trademark laws. The correct version of this news story can be viewed at https://www.com-unik.info/2017/10/31/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-vericel-corporation-vcel-stock-price.html.
About Vericel Corporation
Vericel Corporation, formerly Aastrom Biosciences, Inc, is a commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases segment.
What are top analysts saying about Vericel Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Vericel Corporation and related companies.